• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Neurology

Ocrelizumab associated with lower progression rates for primary progressive multiple sclerosis: The ORATORIO trial

byDavid ArsaniousandShaidah Deghan, MSc. MD
January 19, 2017
in Neurology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. A significant decrease in the rate of clinical and MRI progression was observed for Primary progressive multiple sclerosis (PPMS) patients that received ocrelizumab.

2. Rates of infections, infusion-related reactions, and neoplasms were higher in PPMS patients who received ocrelizumab, although there was a nonsignificant decrease in serious adverse events in patients who received ocrelizumab.

Evidence Rating Level: 1 (Excellent) 

Study Rundown: Primary progressive multiple sclerosis (PPMS) is a form of multiple sclerosis characterized by progressive neurologic decline that begins at the onset of symptoms. As B cells have been implicated in the pathogenesis of PPMS, this study investigated the efficacy and safety of the anti-CD20 monoclonal antibody ocrelizumab in patients with PPMS.

The rates of clinical progression at 12, 24, and 120 weeks were significantly lower in patients who received ocrelizumab compared to placebo at all three time points. There were significant reductions in the progression of T2-hyperintensities and loss of brain volume on MRI at 120 weeks in patients who received ocrelizumab versus placebo. The rates of any adverse event, serious adverse events, adverse events that led to discontinuation of the trial agent, death, infusion-related reactions, serious infections, and neoplasm were higher in patients who received ocrelizumab, although the rates of serious adverse events did not differ significantly between groups.

Click to read the study, published today in NEJM

Relevant Reading: B cell immunobiology in disease: evolving concepts from the clinic

RELATED REPORTS

United States medical cannabis registration increased significantly between 2016 and 2020

Factors associated with earlier clinical symptom onset in radiologically isolated multiple sclerosis

Differences in national strategies for the treatment of relapsing-remitting multiple sclerosis significantly associated with disability outcomes during follow-up

In-Depth [randomized controlled trial]: The ORATORIO study was a phase 3, multi-centre, randomized, parallel-group, double-blind, placebo-controlled, trial. At 12 weeks, disability progression was confirmed in 32.9% of patients in the ocrelizumab group versus 39.3% of patients who received placebo (HR 0.76; 95%CI 0.58 to 0.98; p = 0.03). At 24 weeks, disability progression was confirmed in 29.6% of patients in the ocrelizumab group compared to 35.7% of patients who received placebo (HR 0.75; 95%CI 0.59 to 0.98; p = 0.04). At 120 weeks, worsened performance on the timed 25-foot walk was observed in 38.9% of patients in the ocrelizumab group compared to 55.1% of patients who received placebo (p = 0.04). Between 0 and 120 weeks, the volume of T2 hyperintensities decreased by 3.4% in the ocrelizumab group and increased by 7.4% in patients who received placebo (p < 0.001). Between 24 and 120 weeks, brain volume loss was 0.90% in patients in the ocrelizumab group versus 1.09% in patients who received placebo (p = 0.02). The proportion of patients who had ≥1 infusion-related reaction was 39.9% in patients who received ocrelizumab and 25.5% in patients who received placebo. The proportion of patients who had any serious adverse event was 20.4% in patients who received ocrelizumab and 22.2% of patients who received placebo. The proportion of patients who had serious infections was 6.2% in patients who received ocrelizumab and 5.9% in patients who received placebo. The proportion of patients who developed neoplasms was 2.3% in patients who received ocrelizumab and 0.8% in patients who received placebo.

Image: PD

©2017 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: multiple sclerosis
Previous Post

Asymptomatic women at high risk for Multiple Sclerosis may have early subclinical neuroimaging abnormalities

Next Post

Ocrelizumab decreases multiple sclerosis relapse rate compared to interferon beta-1a

RelatedReports

Parental cannabis use increasing, cigarette use decreasing
Chronic Disease

United States medical cannabis registration increased significantly between 2016 and 2020

June 29, 2022
Asymptomatic women at high risk for Multiple Sclerosis may have early subclinical neuroimaging abnormalities
Chronic Disease

Factors associated with earlier clinical symptom onset in radiologically isolated multiple sclerosis

October 12, 2021
Quick Take: Safety and Efficacy of Ozanimod Versus Interferon Beta-1a in Relapsing Multiple Sclerosis (SUNBEAM)
Chronic Disease

Differences in national strategies for the treatment of relapsing-remitting multiple sclerosis significantly associated with disability outcomes during follow-up

August 17, 2021
Asymptomatic women at high risk for Multiple Sclerosis may have early subclinical neuroimaging abnormalities
Chronic Disease

Improvements in therapeutic and managing standards associated with significant reduction in risk of persistent disability in patients with pediatric-onset multiple sclerosis

June 2, 2021
Next Post
Brain lesions on MRI linked with subsequent increased stroke risk

Ocrelizumab decreases multiple sclerosis relapse rate compared to interferon beta-1a

Intrapartum serum prolactin may predict risk of postpartum diabetes

Diabetes linked to increased mortality in China

AAP reaffirms support for adolescents’ rights to confidential reproductive care

AAP reaffirms support for adolescents’ rights to confidential reproductive care

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Early exposure to allergenic foods may reduce incidence of long-term food allergy
  • Risk of post-vitrectomy endophthalmitis may have increased during the COVID-19 pandemic
  • Bosniak classification system differentiates benign renal cysts from cystic carcinoma [Classics Series]
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.